Viral vectors having enhanced effectiveness with reduced...

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S069100, C435S320100, C435S455000, C435S456000, C424S184100, C424S204100, C424S232100, C424S093100, C424S093200, C424S093600

Reexamination Certificate

active

06846652

ABSTRACT:
The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising the recombinant vaccinia virus are also provided.

REFERENCES:
patent: 6004777 (1999-12-01), Tartaglia et al.
Beattie et al., Virus Genes 12:1, 89-94, 1996.*
U.S. Appl. No. 09/837,998 to Jacobs et al., filed Apr. 19, 2001.
U.S. Appl. No. 09/837,997 to Jacobs et al., filed Apr. 19, 2001.
Beattie et al., “Reversal of the Interferon-Sensitive Phenotype of a Vaccinia Virus Lacking E3L by Expression of the Reovirus S4 Gene”, Journal of Virology, vol. 69, No. 1, Jan. 1995, pp. 499-505.
Brandt et al., “Both Carboxy- and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse Model”, Journal of Virology, vol. 75, No. 1, Jan. 2001, pp. 850-856.
Chang et al., “Indentification of a Conserved Motif That Is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA”, Virology, vol. 194, 1993, pp. 537-547.
Kibler et al., “Double-Stranded RNA Is a Trigger for Apoptosis in Vaccinia Virus-Infected Cells”, Journal of Virology, vol. 71., No. 3, Mar. 1997, pp. 1992-2003.
Shors et al., “Complementation of Vaccinia Virus Deleted of the E3L Gene by Mutants of E3L”, Virology, vol. 239, 1997, pp. 269-276.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Viral vectors having enhanced effectiveness with reduced... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vectors having enhanced effectiveness with reduced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors having enhanced effectiveness with reduced... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3427376

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.